HUMACYTE INSIDERS BUY ZERO‑COST OPTIONS as Company Plans Major Public Offering and Symvess® Launch
Insider buy‑in of 80,000 zero‑cost options amid HUMACYTE’s public offering signals management confidence and a coordinated effort to align incentives with shareholders, but investors should monitor valuation and market sentiment before buying.
3 minutes to read